Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study

Table 2 Comparison of Laboratory Results Before and After the Treatment in Groups (Group 1: Early treatment with FPV and HQ, Group 2: Late treatment with FPV and HQ, Group 3: Treatment with only HQ)

Changes in variables	Group 1		Group 2		Group 3
Changes in variables	Mean ± SD	p	Mean ± SD	p	Mean ± SD	p
CRP	15.2 ± 39.2	0.077	20.2 ± 63.8	0.045	16.2 ± 68.2	0.113
Lymphocyte	− 478.9 ± 930.0	0.066	− 275.5 ± 643.6	0.007	55.1 ± 697.9	0.595
D-Dimer	− 0.74 ± 2.06	0.287	− 0.96 ± 4.71	0.212	0.09 ± 0.63	0.371
Ferritin	− 106.6 ± 280.5	0.287	52.5 ± 254.4	0.276	26.5 ± 487.5	0.739
Cr	− 4.91 ± 8.97	0.052	0.01 ± 0.64	0.902	− 0.68 ± 4.94	0.113
AST	10.4 ± 14.7	0.003	4.2 ± 89.8	0.753	8.2 ± 37.5	0.148
ALT	− 8.2 ± 21.2	0.208	− 4.3 ± 93.7	0.757	− 6.8 ± 28.0	0.101

Statistically significant values are presented in bold. The median values given are the numerical results calculated by the difference of consecutive tests. A negative value means decrease whereas a positive value indicates an increase. The pre and post values of the parameters were compared using the paired sample t test and two-way ANOVA
ALT alanine aminotransferase; AST aspartate aminotransferases; CRP c-reactive protein; Cr creatinin; NS: non-significant

ISSN: 1743-422X